Microfluidic Immunofluorescent Assaying of Circulating and Mobile Tumor Cells and the Development of Blood-based Biomarkers for Clinical Oncology Research

韩平畴 教授

“长江学者”特聘教授，江西中医药大学中西医结合癌症研究中心主任

时间：2019年5月9日（星期四）10:30

地点：卢嘉锡楼202报告厅

厦门大学谱学分析与仪器教育部重点实验室

厦门大学化学化工学院
2019年5月5日

报告摘要：

Microfluidic Immunofluorescent Assaying of Circulating and Mobile Tumor Cells and the Development of Blood-based Biomarkers for Clinical Oncology Research

Ray P.S. Han 韩平畴

Changjiang Chair Professor & Director Integrated Chinese & Western Medicine Oncology Research Center Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China & College of Engineering, Peking University, Beijing, China

Cancer accounts for millions of deaths worldwide and is projected to lead the mortality rates of most countries in the 21st century. This grim situation is fueling the drive for more research to cancer moonshot for the diagnosis, monitoring and treatment of the disease. In this talk, we will present our work in integrating biology, medicine, engineering, physics and mathematics for clinical oncology research. For our first work (in collaboration with Peking Union Medical College and Hospital 北京协和医院) we will discuss a phenotypic profiling of circulating tumor cells (CTCs) for discriminating local and metastatic tumors in pancreatic ductal adenocarcinoma (PDAC) patients. We employed a microfluidic immunofluorescent assay approach to develop a CTC-based blood test by examining the role each phenotype plays in the PDAC metastasis and prognosis. We argued using a multivariable analysis that hybrid-CTCs are a better predictor of metastasis and using a multivariable Cox regression analysis that epithelial-CTCs are a better predictor of overall survival of PDAC patients. The second work (with Zhejiang University 1st Affiliated Hospital 浙江大学医学院附属第一医院) involves the diagnosis of bladder cancer via a microfluidic immunofluorescent enumeration of urothelial exfoliated tumor cells (UETCs) in the urine of bladder cancer patients. We will also discuss the genomic confirmation of UETCs through an evaluation of their copy number alterations. The third work (with Peking Union Medical College and Hospital 北京协和医学院) focuses on a nascent project that involves combining multiple blood-based biomarkers (serum protein, ctDNA, miRNA, CTCs) and a mathematical modeling approach for a very early-stage detection of lung cancer. The simultaneous assaying of multiple biomarkers may yield better quality information for a higher-fidelity detection of lung cancer. We will also discuss the development of a mathematical model based on biophysical laws for a more robust characterization of the shedding of multiple biomarkers in the quest for an individualized growth prediction of an incipient tumor to the point that it becomes detectable by conventional imaging modalities.

报告人简介：

韩平畴，复旦大学、北京大学长江学者特聘教授，北京大学终身教授，美国爱荷华大学终身正教授。多年来，先后从事机械系统、结构振动、航天工程、非线性力学、计算力学、纳米力学、纳米电子、生物医学工程和数码人的研究，除担任5个国际杂志主编、副主编及编委等职务外，还一直为国际工程力学方面的15个杂志审稿，组织和主持在亚洲、加拿大和美国召开的工程力学方面的国际会议10余次，担任这些学术会议的组委会成员和主席，曾多次被指定为国际会议的国际顾问委员会成员，并多次受邀在国际力学会议上做特邀报告，是美国国家基金委、加拿大自然科学工程研究会项目评审专家，加拿大、美国及亚洲等国一些大学的外邀评审专家。1987年至今发表论文220余篇，其中被SCI、EI收录120余篇。从事科学研究以来，承担过加拿大、美国和中国的自然科学基金项目和航天科技项目，涉及到航天动力学、多体动力学、非线性动力学、结构力学、机械振动、有限元方法、流固耦合、机械状况监测等研究领域，成绩显著，是北美工程力学方面中青年优秀学者和科学家。近年来在开展基于微流控系统的稀有细胞捕获及其在癌症诊断领域的应用研究取得了突破性成绩。